AstraZeneca eyes year-end filing for BP drug Baxdrostat

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-09-01 06:56 GMT | Update On 2025-09-01 06:56 GMT

Bengaluru: AstraZeneca plans to seek regulatory approval for its experimental blood pressure drug, baxdrostat, by the end of the year, a senior company executive stated.

Ruud Dobber, president of AstraZeneca’s biopharmaceuticals unit, confirmed the timeline ahead of a presentation of advanced clinical trial data at a medical conference on Saturday. The company is targeting potential approvals in 2026, starting with the United States and the European Union.

Baxdrostat targets blood pressure-regulating hormone aldosterone, a novel approach compared with older treatments like diuretics and ACE inhibitors, which do not address hormonal drivers.

AstraZeneca expects peak annual sales for the drug to exceed $5 billion, Reuters

Keenly watched data showed that 2mg of baxdrostat, added to standard treatment, reduced systolic blood pressure by 9.8 millimetres of mercury (mmHg) from the baseline at 12 weeks, when adjusted for placebo, in patients with hard-to-control hypertension.

At the 1mg dose, that pressure exerted on the arteries by the heart's pumping action was lowered by 8.7 mmHg.

Physicians polled by TD Cowen wished to see a 10-12 mmHg fall in placebo-adjusted blood pressure, the brokerage said on Friday.

Mineralys Therapeutics' rival drug, lorundrostat, in March showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg at six weeks with a 50mg dose. The U.S. company also expects to submit data to the FDA by year-end.

"There's a huge acknowledgement that hypertension needs to be treated in a much more aggressive way," Dobber said.

High blood pressure affects over 1 billion people, according to the World Health Organization, and aggravates risk of heart attacks or strokes.

A small percentage of patients - 1.1% - taking baxdrostat developed hyperkalaemia, marked by high potassium levels in the blood. Hyperkalaemia was also observed with Mineralys' lorundrostat.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca eyes year-end filing for BP drug Baxdrostat

Similar News

Bayer Canada partners with Mint Pharma for distribution of ADALAT XL 30 mg tablets in Canada

AstraZeneca Koselugo recommended for approval in EU for plexiform neurofibromas in adults with neurofibromatosis type 1

AbbVie submits new drug application to USFDA for Tavapadon for Parkinsons disease

Patna Shocker: Pharma Representative Brutally Murdered, Probe Underway

Delhi ITAT Deletes Rs 14.98 Cr Ad-Hoc Disallowance on Mankind Pharma's Travel Expenses

Delhi Govt Bans Genetic Sample Transfers, Tightens Abortion Pill Sales to Curb Sex-Selective Practices

CDSCO Panel Recommends Updating Prescribing Information for Sanofi's Vaccine

Eli Lilly Kisunla gets marketing authorization from European Commission for early symptomatic Alzheimer's disease